Clinical Trials | October 01, 2025
Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
The new site enables end-to-end production of viral vector gene therapies
BIL also holds an option to increase its equity stake by an additional 15%
The CSR initiative will offer Digital Radiology X-Ray service to Dholera and 33 surrounding villages in the region
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The lab will facilitate the development of herbal and natural-based solutions
Encouraging early detection and breaking the silence around men’s health
Subscribe To Our Newsletter & Stay Updated
